Key points are not available for this paper at this time.
On February 9, the Drug Safety and Risk Management Advisory Committee of the FDA voted to recommend a “black-box” warning describing the cardiovascular risks of stimulant drugs used to treat ADHD. Dr. Steven Nissen explains why the advisory committee took decisive action.
Steven E. Nissen (Tue,) studied this question.